Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$0.3 - $0.46 $4,011 - $6,150
13,371 Added 43.84%
43,873 $14,000
Q2 2022

Aug 15, 2022

BUY
$0.32 - $0.67 $9,760 - $20,436
30,502 New
30,502 $11,000
Q2 2021

Aug 16, 2021

SELL
$2.83 - $4.2 $67,237 - $99,787
-23,759 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$2.92 - $5.06 $347,617 - $602,377
-119,047 Reduced 83.36%
23,759 $80,000
Q4 2020

Feb 16, 2021

SELL
$2.22 - $3.78 $10,505 - $17,886
-4,732 Reduced 3.21%
142,806 $400,000
Q3 2020

Nov 16, 2020

SELL
$2.39 - $13.08 $48,457 - $265,197
-20,275 Reduced 12.08%
147,538 $370,000
Q2 2020

Aug 14, 2020

SELL
$6.67 - $13.58 $342,124 - $696,558
-51,293 Reduced 23.41%
167,813 $2.28 Million
Q1 2020

May 15, 2020

SELL
$4.1 - $10.24 $496,382 - $1.24 Million
-121,069 Reduced 35.59%
219,106 $1.66 Million
Q4 2019

Feb 18, 2020

SELL
$3.16 - $6.73 $79,543 - $169,407
-25,172 Reduced 6.89%
340,175 $2.15 Million
Q3 2019

Nov 14, 2019

SELL
$3.55 - $5.4 $2.02 Million - $3.07 Million
-569,303 Reduced 60.91%
365,347 $1.43 Million
Q2 2019

Aug 14, 2019

BUY
$4.1 - $8.05 $1.42 Million - $2.79 Million
346,242 Added 58.84%
934,650 $4.52 Million
Q1 2019

May 15, 2019

BUY
$5.41 - $8.73 $1.03 Million - $1.66 Million
190,604 Added 47.91%
588,408 $4.82 Million
Q4 2018

Feb 14, 2019

BUY
$5.39 - $9.15 $494,182 - $838,917
91,685 Added 29.95%
397,804 $2.2 Million
Q3 2018

Nov 14, 2018

BUY
$7.44 - $10.65 $609,336 - $872,235
81,900 Added 36.53%
306,119 $2.7 Million
Q2 2018

Aug 14, 2018

BUY
$9.15 - $11.34 $208,620 - $258,552
22,800 Added 11.32%
224,219 $2.24 Million
Q1 2018

May 15, 2018

BUY
$9.53 - $15.68 $1.92 Million - $3.16 Million
201,419 New
201,419 $1.92 Million

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $417M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.